/EINPresswire.com/ -- WILMINGTON, DE -- (Marketwired) -- 02/02/16 -- NeuroRx, Inc., a clinical stage pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders, today announced that its chief executive officer, Jonathan Javitt, M.D., will deliver a corporate presentation and Cyclurad™ update at the 18th BIO CEO & Investor Conference, being held February 8-9, 2016, in New York.

Details of the presentation are as follows:

• 18th BIO CEO & Investor Conference 2016
  Time/Date: 1:00 p.m. ET on Monday, February 8, 2016
  Location: The Waldorf Astoria Hotel, New York
  Room: Park North
  Track: CNS/Neurological

About Cyclurad™

Cylurad™ is being developed as a rapid-onset and sustained treatment for acute suicidal crisis associated with bipolar depression. Cyclurad combines D-cycloserine, an N-methyl-D-aspartate (NMDA) receptor modulator; and lurasidone, a 5-HT2a receptor antagonist. NeuroRx's investigational treatment approach begins with a single dose of ketamine, an FDA approved anesthetic, followed by approximately six weeks of daily oral Cyclurad. Peer-reviewed and published results from two Phase II clinical studies demonstrate a significant decline in symptoms of depression following administration of D-cycloserine. Findings from one of these studies found that bipolar patients who were already receiving a 5-HT2a antagonist demonstrated more than a 50% reduction in symptoms of depression and a 75% reduction in suicidal ideation when ketamine and D-cycloserine were added to their treatment regimen. Cyclurad is being developed as a convenient, oral, fixed-dose combination of an 5-HT2a antagonist and D-cycloserine, to be administered following a single dose of ketamine.

About NeuroRx, Inc.

NeuroRx, Inc. is a clinical stage pharmaceutical company that is developing Cylurad™, the first oral therapeutic for the treatment of suicidal crisis associated with bipolar disorder. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain's N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific. NeuroRx expects to initiate a Phase II/III clinical trial of Cyclurad in combination with ketamine for the treatment of acute suicidal crisis in bipolar depression during the first half of 2015. More information at www.neurorxpharma.com

Contacts:

Vida Strategic Partners
Stephanie Diaz (Investors)
Email Contact
415-675-7401

Tim Brons (Media)
Email Contact
(646) 319-8981

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.